New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Brought to you by 
Lilly licenses Amylin's diabetes drug; deal ends with rights returned to Amylin
Sep 2002
Executive Summary
Eli Lilly will collaborate on further clinical development and commercialization of Amylin Pharmaceuticals' (treatments for diabetes and other metabolic diseases) AC2993 (exenatide), a Phase III candidate for Type II diabetes.
Deal Industry
-
Biotechnology
- Large Molecule
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Co-Promotion
- Includes Contract
- Product or Technology Swap
- R+D and Marketing-Licensing
- Includes Equity
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly licenses Amylin's diabetes drug; deal ends with rights returned to Amylin
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice